Methods and compositions for treating hepatitis c virus

Abstract

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

1 - 30 . (canceled) 
     
     
         31 . A method for the treatment of a hepatitis C virus infection in a host, comprising administering to said host an anti-virally effective amount of a β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof. 
     
     
         32 . The method of  claim 31 , wherein an anti-virally effective amount of a β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable ester thereof is administered. 
     
     
         33 . The method of  claim 32 , wherein the nucleoside is a pyrimidine nucleoside. 
     
     
         34 . The method of  claim 33 , wherein the J3-D-2′-methylpyrimidine nucleoside is administered in combination or alternation with a second anti-hepatitis C agent. 
     
     
         35 . The method of  claim 34 , wherein the second anti-hepatitis C agent is an interferon. 
     
     
         36 . The method of  claim 34 , wherein the second anti-hepatitis C agent is ribavirin. 
     
     
         37 . The method of  claim 34 , wherein the second anti-hepatitis C agent is an interferon, ribavirin or a combination thereof. 
     
     
         38 . The method of  claim 31 , wherein the nucleoside is a pyrimidine nucleoside. 
     
     
         39 . The method of  claim 38 , wherein the β-D-2′-methylpyrimidine nucleoside is administered in combination or alternation with a second anti-hepatitis C agent. 
     
     
         40 . The method of  claim 39 , wherein the second anti-hepatitis C agent is an interferon. 
     
     
         41 . The method of  claim 39 , wherein the second anti-hepatitis C agent is ribavirin. 
     
     
         42 . The method of  claim 39 , wherein the second anti-hepatitis C agent is an interferon, ribavirin or a combination thereof. 
     
     
         43 . The method of  claim 31 , wherein the β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is in a tablet or capsule. 
     
     
         44 . The method of  claim 31 , wherein a unit dose of the β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof is administered. 
     
     
         45 . The method of  claim 43 , wherein the tablet or capsule contains 50 to 1000 mg of the β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof. 
     
     
         46 . The method of  claim 44 , wherein the unit dose contains 50 to 1000 mg of the β-D-2′-methyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof. 
     
     
         47 . The method of  claim 31 , wherein the nucleoside is a β-D-2′-methyl-2′-halo nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof. 
     
     
         48 . The method of  claim 47 , wherein an anti-virally effective amount of a β-D-2′-methyl-2′-halo nucleoside or a phosphate thereof, or a pharmaceutically acceptable ester thereof is administered. 
     
     
         49 . The method of  claim 33 , wherein the nucleoside is a β-D-2′-methyl-2′-halo pyrimidine nucleoside. 
     
     
         50 . A method for the treatment of a hepatitis C virus infection in a host, comprising administering to the host an anti-virally effective amount of a compound of Formula XI: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or ester thereof; 
       wherein:
 Base is a pyrimidine base; 
 R 1  and R 2  are each independently H or phosphate; 
 R 6  is alkyl; 
 R 7  is halo; and 
 X is O. 
 
     
     
         51 . The method of  claim 50 , wherein Base is uracil. 
     
     
         52 . The method of  claim 51 , wherein R 6  is methyl. 
     
     
         53 . The method of  claim 52 , wherein R I  is phosphate. 
     
     
         54 . The method of  claim 53 , wherein R 2  is H. 
     
     
         55 . The method of  claim 50 , wherein the compound of Formula XI is administered in combination or alternation with a second anti-hepatitis C agent. 
     
     
         56 . The method of  claim 55 , wherein the second anti-hepatitis C agent is an interferon. 
     
     
         57 . The method of  claim 55 , wherein the second anti-hepatitis C agent is ribavirin. 
     
     
         58 . The method of  claim 55 , wherein the second anti-hepatitis C agent is an interferon, ribavirin or a combination thereof. 
     
     
         59 . The method of  claim 54 , wherein the compound of Formula XI is administered in combination or alternation with a second anti-hepatitis C agent. 
     
     
         60 . The method of  claim 59 , wherein the second anti-hepatitis C agent is an interferon, ribavirin or a combination thereof.